IN8bio, Inc. (INAB)
INABNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.9401
0.0000 (0.00%) today
Pre-market, Nov 9, 4:00 PM ET
- Market cap
- $10.16m
- P/E
- –
- EPS, last 4 quarters
- $-1.01
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8000 to $2.73
- Average volume
- 41.1k
- Previous close
- $0.9401
Analysts
3 coveringBuy2 buy, 1 hold, 0 sell
Targets a year out average $5.50, +485.0% from here
Earnings
next estimate $-0.6500Next report
Dec 2025
-44.4%
Mar 2026
+55.9%
Jun 2026
+59.0%
Sep 2026
+57.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.97m | -$5.03m | -$5.27m | -$4.93m |
| Net income | -$3.85m | -$4.94m | -$5.09m | -$4.78m |
News
8 latest- IN8bio Consensus Price Target Raised 12% to $7.14Fintel · Oct 2, 2026
- IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks · Jun 4, 2026
- IN8bio Announces Private Placement Financing RTTNews · Dec 19, 2025
- IN8bio (INAB) Q2 Loss Narrows 77%The Motley Fool · Aug 7, 2025
- IN8bio Reports Promising Phase 1 Trial Results for INB-200, Demonstrating 16.1 Months Median Progression-Free Survival in Glioblastoma PatientsQuiver Quantitative · Jun 2, 2025
- IN8bio to Participate in Immuno-Oncology 360° Conference 2025, Highlighting Advances in Gamma-Delta T Cell TherapiesQuiver Quantitative · Mar 18, 2025
- IN8BIO Earnings Results: $INAB Reports Quarterly EarningsQuiver Quantitative · Mar 13, 2025
- IN8bio Reports Strong Clinical Progress and Expands Pipeline with Innovative Gamma-Delta T Cell TherapiesQuiver Quantitative · Mar 13, 2025
The company
IN8bio is a clinical-stage biopharmaceutical company developing T cell and T cell engager (TCE) product candidates to address unmet medical needs. T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's pipeline is anchored by INB-600, a novel T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also developing INB-100, an allogeneic T cell therapy candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified T cell therapy candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.in8bio.com.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- in8bio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.